Navigation Links
Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
Date:12/6/2013

," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding the settlement of the Notes and the anticipated use of proceeds from the offering. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2013 and its other reports, which are available from the SEC's website (www.sec.gov). All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.Orexigen Contact: Media Contact: McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... September 03, 2015 , ... At Renew Man™, we have seen an increasing ... care model, where the primary care physician dictates and the patient obeys. Instead, our ... about their health issues and empowered to choose their own treatment options. , Recognizing ...
(Date:9/3/2015)... Kingston, NY (PRWEB) , ... September 03, 2015 , ... ... on iTunes, April Hannah & Michael Habernig from Path 11 Productions have had great ... This new age podcast has featured Hay House authors, Teal Swan who is the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa ... health professionals out there. His perspective on internal medicine keeps patients happy and healthy, ... healthy is important regardless of the season, but even more so in the fall, ...
(Date:9/2/2015)... ... September 03, 2015 , ... The Aspen Clinic (TAC), ... retreats geared towards kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. ... developing a whole mind-body approach to fitness - we are much more than a ...
Breaking Medicine News(10 mins):Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:TAC Introduces New Retreats for Fall Fitness 2
... An international team of cancer specialists and imaging ... response to treatment//. The guidelines will provide clinicians ... clinical trials of lymphoma treatments and should facilitate ... guidelines developed by the International Harmonization Project (IHP) ...
... born to mothers who smoked during pregnancy may find ... study//. ,A recent animal research suggests that ... find it difficult to quit smoking. Duke University Medical ... to nicotine is known to alter areas of the ...
... insurance to around 1.2 million families below the poverty ... ,"We are aware of the health challenges and ... decided to provide health insurance to BPL families, and ... project this year," Kumaraswamy said in Ingalagi village in ...
... suffering from asthma compared to other methods of ... of different medicines. ,Although several ... clinical trials directly comparing them have not been ... ,For the first time, researchers in the Childhood ...
... Some obese have not looked up from their plate full of ... for the free obesity surgery.// ,Earlier, the government ... medical condition could get the obesity surgery done, free of cost. ... avail the free surgery offered by the government. ,People ...
... stress and depression,// may be associated with higher ... in turn are related to an increased risk for ... 22 issue of Archives of Internal Medicine, one of ... studies have linked psychosocial characteristics with cardiovascular disease and ...
Cached Medicine News:Health News:New Guidelines For Assessing Lymphoma Treatment 2Health News:New Guidelines For Assessing Lymphoma Treatment 3Health News:Quitting Not Easy for Smokers Born to Smoking Women 2Health News:Karnataka's Free Health Insurance to the Poor 2Health News:Psychosocial Factors Associated With Higher Levels of Inflammatory Markers 2
... With the increase in Endoscopic cases it is ... Monitor with the Surgical Light. This combination ... without having to adopt an uncomfortable pose. ... including the NUVO Monitoring System. As such ...
... This configuration offers all the performance of a ... perfectly for use in Outpatient Settings, Minor Procedure ... Mounting two single lights either side of the ... in a General OR when combining Flat Screen ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
Medicine Products: